OTCMKTS:RCDTF Recordati Industria Chimica e Farmaceutica (RCDTF) Stock Price, News & Analysis $56.04 0.00 (0.00%) As of 05/5/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestBuy This Stock About Recordati Industria Chimica e Farmaceutica Stock (OTCMKTS:RCDTF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RCDTF alerts:Sign Up Key Stats Today's Range$56.04▼$56.0450-Day Range$49.00▼$56.0452-Week Range$49.00▼$56.04VolumeN/AAverage Volume863 shsMarket Capitalization$11.56 billionP/E Ratio28.02Dividend YieldN/APrice TargetN/AConsensus RatingReduce Company OverviewRecordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.Read More… Receive RCDTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recordati Industria Chimica e Farmaceutica and its competitors with MarketBeat's FREE daily newsletter. Email Address RCDTF Stock News HeadlinesRecordati Industria Chimica e Farmaceutica SPA (0KBS) Receives a Hold from RBC CapitalApril 26, 2025 | markets.businessinsider.comRecordati, la Fda amplia l’uso del farmaco Isturisa. Ma il titolo cade in borsa, ecco perchéApril 18, 2025 | msn.comAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.May 6, 2025 | Paradigm Press (Ad)3 European Stocks Estimated To Be Trading At Discounts Of Up To 40.1%April 17, 2025 | finance.yahoo.comRecordati Industria Chimica e Farmaceutica S.p.A.April 7, 2025 | uk.investing.comRecordati upgraded to Hold from Sell at Deutsche BankMarch 19, 2025 | markets.businessinsider.comRecordati Reports Strong 2024 Financial Results and Reaffirms ESG CommitmentMarch 18, 2025 | msn.comRecordati price target raised to EUR 55 from EUR 53 at RBC CapitalMarch 16, 2025 | markets.businessinsider.comSee More Headlines RCDTF Stock Analysis - Frequently Asked Questions How have RCDTF shares performed this year? Recordati Industria Chimica e Farmaceutica's stock was trading at $55.54 at the beginning of 2025. Since then, RCDTF stock has increased by 0.9% and is now trading at $56.0428. View the best growth stocks for 2025 here. How do I buy shares of Recordati Industria Chimica e Farmaceutica? Shares of RCDTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/06/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:RCDTF Previous SymbolNASDAQ:RCDTF CIKN/A Webwww.recordati.com Phone390-248-7871Fax39-02-4007-3747Employees4,455Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$2.00 Trailing P/E Ratio28.02 Forward P/E RatioN/A P/E GrowthN/ANet Income$421.25 million Net Margins17.41% Pretax MarginN/A Return on Equity30.78% Return on Assets12.65% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$2.25 billion Price / Sales5.13 Cash Flow$3.09 per share Price / Cash Flow18.15 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares206,300,000Free FloatN/AMarket Cap$11.56 billion OptionableNot Optionable Beta0.26 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (OTCMKTS:RCDTF) was last updated on 5/6/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredREVEALED: Elon’s Secret Master Plan “AGENDA X”REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secre...Brownstone Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recordati Industria Chimica e Farmaceutica S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recordati Industria Chimica e Farmaceutica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.